Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Irinotecan Hydrochloide
Generic Name
Irinotecan Hydrochloide
Active Ingredient
IrinotecanCategory
Other
Salt Form
Hydrochloride
Variants
2
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Irinotecan Hydrochloide, you must consult a qualified healthcare professional.
Detailed information about Irinotecan Hydrochloide
Irinotecan is a potent antineoplastic agent belonging to the topoisomerase I inhibitor class. It is primarily used in the treatment of metastatic colorectal cancer and other solid tumors by inhibiting DNA replication in cancer cells.
Dosing for Irinotecan is highly individualized and is calculated based on the patient's Body Surface Area (BSA), measured in square meters (m²). There are two primary dosing schedules used in clinical practice:
Your oncologist may start with a lower dose (e.g., 100 mg/m² or 300 mg/m²) if you have certain risk factors, such as being over the age of 70, having received prior pelvic radiation, or having a known genetic variation (UGT1A1*28 polymorphism) that affects drug metabolism.
Irinotecan is not currently FDA-approved for use in pediatric patients. While it is sometimes used 'off-label' in specialized pediatric oncology settings for certain childhood solid tumors (like neuroblastoma or rhabdomyosarcoma), safety and effectiveness have not been formally established in patients under the age of 18. Dosing in these cases is strictly managed by pediatric oncology specialists and is often based on weight or BSA.
There are no specific formal guidelines for dosing Irinotecan in patients with renal (kidney) impairment, as the primary route of elimination is hepatic. However, healthcare providers exercise extreme caution and may monitor kidney function closely, as dehydration from Irinotecan-induced diarrhea can lead to acute kidney injury.
Since the liver is the primary site for converting Irinotecan to its active form and for its subsequent inactivation, hepatic function is critical. Patients with a total bilirubin level between 1.0 and 2.0 mg/dL have a significantly higher risk of severe neutropenia. Dosing is generally not recommended if the bilirubin is greater than 2.0 mg/dL, or if the patient has significant liver dysfunction (Child-Pugh Class B or C).
Patients over the age of 65 (and especially those over 70) are at a higher risk of severe dehydration and electrolyte imbalances due to diarrhea. For the once-every-3-weeks schedule, a reduced starting dose of 300 mg/m² is often recommended for patients aged 70 or older.
Irinotecan must be administered in a clinical setting (hospital or infusion center) by trained medical personnel. It is not available for self-administration at home.
Because Irinotecan is administered on a strict clinical schedule, missing a dose can interfere with the effectiveness of the treatment. If you miss an appointment for your infusion, contact your oncology clinic immediately to reschedule. Do not attempt to 'double up' or take any other medications to compensate for a missed dose.
An overdose of Irinotecan is a medical emergency and typically occurs due to a calculation error in the clinical setting. The primary symptoms of overdose are severe, life-threatening neutropenia (low white blood cells) and severe diarrhea. Treatment is supportive, focusing on intensive hydration, electrolyte replacement, and the administration of colony-stimulating factors (like G-CSF) to boost white blood cell production. There is no specific antidote for Irinotecan overdose.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your treatment schedule without direct medical guidance from your oncology team.
Irinotecan is associated with a high frequency of side effects, some of which require proactive management.
Irinotecan is a high-alert medication that requires strict medical supervision. Patients must be educated on the 'loperamide protocol' for late-onset diarrhea before receiving their first dose. Because this drug can significantly suppress the immune system, patients should avoid contact with people who have active infections and should not receive 'live' vaccines during treatment.
Certain drugs should never be used with Irinotecan because they can cause dangerous changes in how the drug is processed:
Irinotecan must NEVER be used in the following circumstances:
In these cases, a doctor will perform a careful risk-benefit analysis:
Irinotecan is classified as FDA Pregnancy Category D. This means there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. In animal studies, Irinotecan caused significant birth defects and fetal death at doses lower than those used in humans.
It is not known whether Irinotecan or its metabolites are excreted in human milk. However, because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants (including cancer-causing potential and immune suppression), breastfeeding is not recommended during treatment. You should wait at least 7 days after your last dose before resuming breastfeeding.
Irinotecan is a semi-synthetic derivative of camptothecin. Its primary mechanism of action is the inhibition of topoisomerase I. During DNA replication, this enzyme creates single-strand nicks to relieve torsional strain. Irinotecan's active metabolite, SN-38, binds to the DNA-topoisomerase I complex, preventing the re-ligation of these nicks. This results in the formation of lethal double-strand DNA breaks when the replication fork collides with the stalled complex. This process is S-phase specific, meaning it primarily kills cells that are actively synthesizing new DNA.
The pharmacodynamics of Irinotecan are characterized by a clear dose-response relationship regarding both tumor shrinkage and toxicity. The 'cholinergic' effects (early diarrhea, sweating) are pharmacodynamic responses to the drug's inhibition of acetylcholinesterase. The anti-tumor effect is delayed, as it depends on the cell cycle progression of the tumor cells.
| Parameter | Value |
|---|---|
Common questions about Irinotecan Hydrochloide
Irinotecan is primarily used to treat advanced or metastatic colorectal cancer, which is cancer of the colon or rectum that has spread to other parts of the body. It is often used in combination with other chemotherapy drugs like 5-fluorouracil and leucovorin in a regimen known as FOLFIRI. Additionally, it may be used for small cell lung cancer and, in some cases, pancreatic or gastric cancers. It works by blocking an enzyme called topoisomerase I, which cancer cells need to repair and replicate their DNA. By stopping this process, the drug causes the cancer cells to die and helps slow the progression of the disease.
The most common side effects of Irinotecan include severe diarrhea, nausea, vomiting, and a significant drop in white blood cell counts (neutropenia). Diarrhea is particularly notable because it can occur in two phases: an early phase during the infusion and a late phase that starts more than 24 hours later. Other frequent side effects include hair loss (alopecia), extreme fatigue, abdominal cramping, and a temporary increase in liver enzymes. Many patients also experience 'cholinergic' symptoms during the infusion, such as sweating, runny nose, and increased salivation. Because these side effects can be severe, they require close monitoring by an oncology team.
It is generally recommended that you avoid or strictly limit alcohol consumption while receiving Irinotecan treatment. Alcohol can worsen several of the drug's side effects, including nausea, dizziness, and dehydration. Since Irinotecan is processed by the liver, adding alcohol can increase the stress on this organ and potentially interfere with the drug's metabolism. Furthermore, alcohol can irritate the lining of the digestive tract, which may increase the severity of Irinotecan-induced diarrhea. Always consult your oncologist before consuming any alcohol during your chemotherapy cycles.
No, Irinotecan is not considered safe during pregnancy and is classified as FDA Category D. Clinical data and animal studies indicate that the drug can cause significant harm to a developing fetus, including birth defects and miscarriage. Women of childbearing age must use highly effective birth control during treatment and for several months afterward. If you become pregnant while taking Irinotecan, you must inform your doctor immediately to discuss the risks. Men taking the drug should also use contraception to avoid fathering a child during treatment, as the drug can affect sperm.
Irinotecan begins working at the cellular level almost immediately after the infusion starts, but visible results like tumor shrinkage usually take several weeks or months to appear. Typically, doctors will perform imaging scans (like CT or PET scans) after 2 or 3 cycles of treatment (roughly 6 to 9 weeks) to evaluate how the cancer is responding. The effectiveness of the drug varies significantly between patients based on their specific type of cancer and genetic factors. Even if you do not feel 'better' right away, the drug may still be effectively killing cancer cells. Your oncology team will monitor your progress closely through blood tests and scans.
Because Irinotecan is administered by healthcare professionals in a clinic, you cannot stop taking it in the traditional sense of a daily pill. However, you can choose to discontinue your chemotherapy treatment at any time. It is vital to discuss this decision with your oncologist first, as stopping treatment can allow the cancer to grow or spread more quickly. If treatment is stopped due to severe side effects, your doctor will provide supportive care to help your body recover. There are no withdrawal symptoms associated with Irinotecan, but the effects on your blood counts and digestion may last for several weeks after the final dose.
If you miss an appointment for your Irinotecan infusion, you should contact your oncology clinic as soon as possible to reschedule. Chemotherapy is most effective when given on a precise schedule to catch cancer cells at specific points in their growth cycle. Missing a dose or delaying treatment can potentially allow the cancer to progress. Your doctor will determine the best way to adjust your schedule based on why the dose was missed and how you have been tolerating the treatment. Do not attempt to take any other medications to make up for the missed infusion.
Weight gain is not a typical side effect of Irinotecan; in fact, weight loss is much more common. The frequent nausea, vomiting, and severe diarrhea associated with the drug often lead to a decreased appetite and fluid loss, which can result in weight loss. If you do experience rapid weight gain or swelling (edema) in your legs or abdomen, you should report this to your doctor immediately. This could be a sign of a different complication, such as kidney issues or a reaction to other medications like steroids (e.g., dexamethasone) that are often given alongside Irinotecan to prevent nausea.
Irinotecan has several significant drug interactions, so it must be used cautiously with other medications. It is especially dangerous when combined with strong CYP3A4 inhibitors (like ketoconazole) or inducers (like St. John's Wort), which can either cause toxic drug levels or make the treatment ineffective. You should also avoid taking laxatives unless specifically directed by your oncologist, as they can worsen Irinotecan-induced diarrhea. Always provide your healthcare team with a complete list of all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you are taking to ensure your safety during treatment.
Yes, Irinotecan hydrochloride is available as a generic medication. The brand name version, Camptosar, was the original formulation, but several pharmaceutical companies now produce generic versions that are therapeutically equivalent. Generic Irinotecan is generally more cost-effective for patients and insurance providers while maintaining the same standards for safety and efficacy. However, there is also a liposomal version of Irinotecan (brand name Onivyde) which is a different formulation and is not currently available as a generic. Your doctor will prescribe the specific version that is appropriate for your condition.
Other drugs with the same active ingredient (Irinotecan)
> Warning: Stop your activities and call your doctor or seek emergency care immediately if you experience any of the following:
While most side effects of Irinotecan resolve after the medication is stopped, some patients may experience lasting effects:
Irinotecan carries two major FDA Black Box Warnings, the highest level of caution for a medication:
Report any unusual symptoms, especially changes in bowel habits or signs of infection, to your healthcare provider immediately.
To ensure safety, your healthcare team will perform the following tests regularly:
Irinotecan can cause dizziness, visual disturbances, and profound fatigue within 24 hours of administration. Patients are advised to avoid driving or operating heavy machinery until they are certain the medication is not affecting their alertness.
Alcohol should be avoided or strictly limited during Irinotecan treatment. Alcohol can worsen the nausea and dehydration caused by the drug and may put additional strain on the liver, which is already working hard to metabolize the chemotherapy.
Irinotecan does not cause a 'withdrawal syndrome,' but it is rarely stopped abruptly unless severe toxicity occurs. Usually, treatment continues until the cancer progresses or the side effects become unmanageable. If you must stop treatment, your doctor will monitor you closely for several weeks to ensure your blood counts recover.
> Important: Discuss all your medical conditions, especially any history of liver disease or bowel problems, with your healthcare provider before starting Irinotecan.
Irinotecan does not typically interfere with the chemical results of lab tests, but it will significantly alter the values themselves (e.g., lowering white blood cell counts or raising liver enzymes). Always inform any lab technician that you are undergoing chemotherapy.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs like aspirin or ibuprofen.
There is a potential for cross-sensitivity between Irinotecan and other camptothecin derivatives, such as Topotecan. If you have had a reaction to Topotecan, your doctor will exercise extreme caution when administering Irinotecan.
> Important: Your healthcare provider will evaluate your complete medical history, including genetic factors and prior treatments, before prescribing Irinotecan.
As previously noted, Irinotecan is not FDA-approved for use in children. Clinical trials in pediatric patients have shown that while the drug is processed similarly to adults, the side effect profile—particularly the risk of severe diarrhea—can be more difficult to manage in small children. Use in this population is strictly limited to clinical trials or specialized tertiary care centers.
Patients over the age of 65 are at a significantly higher risk of 'late' diarrhea and severe dehydration. Clinical data shows that the risk of Grade 3 or 4 diarrhea is much higher in the elderly. For the every-3-week dosing schedule, doctors typically start patients aged 70+ at a lower dose of 300 mg/m². Close monitoring of fluid intake and output is essential for older adults.
While the kidneys are not the primary route of elimination, renal function can be compromised by the side effects of Irinotecan. If a patient becomes severely dehydrated from diarrhea, they can develop 'prerenal' azotemia (a buildup of nitrogen waste in the blood). There are no specific dose adjustments for baseline renal impairment, but the drug must be used with caution in those with pre-existing kidney disease.
The liver is the central hub for Irinotecan activity. Patients with elevated bilirubin levels (between 1.0 and 2.0 mg/dL) have a much higher risk of severe neutropenia. If the bilirubin is above 2.0 mg/dL, the drug is generally not recommended. For patients with AST/ALT levels more than 5 times the normal limit, the safety of Irinotecan has not been established.
> Important: Special populations require individualized medical assessment and often more frequent lab monitoring.
| Protein Binding | 30-68% (Irinotecan); 95% (SN-38) |
| Half-life | 6-12 hours (Irinotecan); 10-20 hours (SN-38) |
| Tmax | End of 90-minute infusion |
| Metabolism | Hepatic (Carboxylesterase to SN-38; UGT1A1 to SN-38G) |
| Excretion | Fecal 64%, Renal 14-37% |
Irinotecan is classified as a Topoisomerase I Inhibitor. It is part of the larger family of antineoplastic agents known as Camptothecins. Other drugs in this class include Topotecan, though Irinotecan is unique due to its prodrug nature and its specific metabolic pathway involving the UGT1A1 enzyme.